CDK4 and pancreatic neoplasm: These observations are in agreement with those reported by Franco et al, who also found that CDK4/6 inhibition leads to an enhanced activation of the mTOR pathway and consequent sensitivity of pancreatic cancer cells to mTOR inhibitors (Franco et al, 2016).